**Core Concept**
Cancer chemotherapy-induced vomiting (CINV) is mediated by activation of the emetic pathway involving the chemoreceptor trigger zone (CTZ) in the brainstem and peripheral chemosensory receptors. Effective antiemetic therapy targets multiple pathways, including serotonin (5-HT3) receptors, neurokinin-1 (NK1) receptors, and corticosteroid modulation of cytokine release.

**Why the Correct Answer is Right**
Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P-mediated vomiting, effective in both acute and delayed CINV. Dexamethasone, a corticosteroid, reduces vomiting by suppressing cytokine release and modulating central nervous system emetic pathways. Ondansetron is a selective 5-HT3 receptor antagonist that blocks emetic signals from the gastrointestinal tract and CTZ. All three drugs are established components of multi-modal antiemetic regimens in oncology.

**Why Each Wrong Option is Incorrect**
Option A: Aprepitant is correct, but the question asks for drugs used — not just one.
Option B: Dexamethasone is correct, but not sufficient alone.
Option C: Ondansetron is correct, but again, not the only agent.
Thus, "all of the above" is the most comprehensive and accurate choice.

**Clinical Pearl / High-Yield Fact**
In high-risk patients (e.g., platinum-based chemo), a combination of ondansetron, aprepitant, and dexamethasone is the gold standard for preventing CINV. This regimen covers both early and delayed phases of vomiting.

✓ Correct Answer: D. All of the above